Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLLS with… →

CLLS Key Statistics

As of Sep 4, 2026

Trading

Open: $3.41
Previous Close: $3.32
Day's Range: 3.21–3.41
52-Week Range: 2.35–5.48
Volume: 4.80K
Beta: 2.77

Valuation

Market Cap: $326.27M
P/E Ratio: unprofitable
P/S ratio: 5.11
EPS (ttm): −0.63

Financials (FY)

Revenue (FY): $72.95M+75.76%
Net Income (FY): −$67.59M
Profit margin: −102.34%
Shares Outstanding: 72.70M
1-Year Return: +23.19%

Dividend and dates

Earnings Date: November 13, 2026estimated
Avg Volume: 23.79K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CLLS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−74.14%+168.89%−33.06%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−33.06%
2025	+168.89%
2024	−41.56%
2023	+46.67%
2022	−74.14%
2021	−69.99%
2020	+58.06%
2019	+2.82%
2018	−42.88%
2017	+71.98%
2016 (partial year)	−38.94%

As of September 4, 2026.

CLLS Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$72.95M	−$67.59M	−92.7%
2024	$41.51M	−$36.76M	−88.6%
2023	$755.00K	−$101.06M	−13385.3%
2022	$19.17M	−$106.14M	−553.6%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$72.95M	$63.15M	−$33.08M	−$67.59M	−92.7%
2024	$41.51M	$32.32M	−$59.55M	−$36.76M	−88.6%
2023	$755.00K	−$6.66M	−$97.30M	−$101.06M	−13385.3%
2022	$19.17M	$10.69M	−$89.67M	−$106.14M	−553.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CLLS Valuation vs Biotechnology Median

Median of 656 stocks

Metric	CLLS	Biotechnology median	vs median
P/S ratio	5.11	15.26	67% below
Profit margin	−102.34%	0.00%	102.3 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cellectis S.A. (CLLS) carries a market capitalisation of $326.27M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 224.

Over the past 52 weeks the price has ranged from $2.35 to $5.48. The most recent close on file for CLLS is $3.24, dated September 4, 2026. That is −$0.08 (−2.41%) against the previous close. The latest close sits 37.87% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $72.95M. Against the prior fiscal year total of $41.51M, that is a change of +75.76%. The same year closed with a net loss of $67.59M. Profit margin runs at −102.34%. That is 102.3 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.63.

Across the 4 fiscal years on file, revenue moves from $19.17M in 2022 to $72.95M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 5.11. On price-to-sales that is 66.51% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +23.19%. Measured over 10 years, that is −18.92% a year compounded. Beta against the wider market is reported at 2.77. Annualized volatility over the trailing 10 years is 89.42%.

Growth & Income

The record shows no dividend for CLLS.

2026 is still running; the price is −33.06% year to date. The strongest complete calendar year on file is 2025 at +168.89%; the weakest is 2022 at −74.14%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Cellectis S.A. (CLLS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Cellectis S.A.	CLLS	$326.27M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Cellectis S.A. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Visit website →

Cellectis S.A. (CLLS) Stock Analysis